AstraZeneca, which is developing the vaccine against the coronavirus SARS-CoV-2, announced the clinical advance of a new medical therapy to apply in 6,000 people already infected and prevent them from reaching a serious state of the disease.
The laboratory announced on Friday that AstraZeneca’s Long-Acting Antibody (LAAB) combination, AZD7442, will advance in the coming weeks in conducting two phase III clinical trials in more than 6,000 participants chosen within and outside of the United States.
The country’s government has awarded $486 million to AstraZeneca for the development and supply of up to 100,000 doses and can acquire another one million doses.
LAABs are designed with the latest AstraZeneca proprietary technology to increase the durability of therapy from 6 to 12 months after a single administration. The combination of two LAABs is also designed to reduce the risk of resistance developed by the SARS-CoV-2 virus.